Prevalence of cardiovascular diseases and type 2 diabetes mellitus in perimenopausal women with a history of the polycystic ovary syndrome
https://doi.org/10.18705/1607-419X-2009-15-2-218-222
Abstract
The aim of our study was to evaluate the prevalence of type 2 diabetes mellitus (DM), arterial hypertension and coronary artery disease (CAD) in perimenopausal women with a history of polycystic ovary syndrome (PCOS) treatment. A group of 38 women aged 45-59 years, who had been treated for typical symptoms of PCOS in different hospitals of St Petersburg in 1972-1989 years, were included in the study. An age-matched sample of women without PCOS (N = 308) was selected. There was no difference in waist circumference, body mass index and in the proportions of women with obesity between these two groups. The mean fasting glucose was significantly higher and the impaired fasting glucose was found more often in PCOS women, than in controls. The mean concentrations of lipids showed no difference in the groups. Patients with PCOS had significantly higher prevalence of type 2 DM and arterial hypertension. There was no difference in the prevalence of CAD.
About the Authors
P. Popova
St Petersburg Pavlov state University
Russian Federation
Russian Federation
E. V. Baranova
St Petersburg Pavlov state University
Russian Federation
Russian Federation
E. N. Grineva
St Petersburg Pavlov state University
Russian Federation
Russian Federation
References
1. Дедов И.И., Мельниченко Г.А. Синдром поликистозных яичников. - М.: Медицинское информационное агентство, 2007. - С. 192.
2.
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis // Endocr. Rev. - 1997. - Vol. 18, № 6. - P. 774-800.
4.
5. Franks S. Polycystic ovary syndrome // N. Engl. J. Med. - 1995. - Vol. 333. - P. 853-861.
6.
7. Dunaif A., Xia J., Book C., Schenker E., Tang Z. Excessive insulin receptor serine рhosphorylation in cultured fibroblasts and skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome // J. Clin. Invest. - 1995. - Vol. 96. - P. 801-810.
8.
9. Morales A.J., Laughlin G.A., Butzow T. et al. Insulin, somatotropic, and luteinizing hormones axes in lean and obese women with рolycystic ovary syndrome: common and distinct features // J. Clin. Endocrinol. Metab. - 1996. - Vol. 81. - P. 2854-2864.
10.
11. Nestler J.E., Powers L.P., Matt D.W. et al. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome // J. Clin. Endocrinol. Metab. - 1991. - Vol. 72. - P. 83-89.
12.
13. Nestler J.E., Jakubowicz D.J., de Vargas A.F. et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system // J. Clin. Endocrinol. Metab. - 1998. - Vol. 80. - P. 2001-2005.
14.
15. Dahlgren E., Johansson S., Lindstedt G. et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow-up focusing on natural history and circulating hormones // Fertil. Steril. - 1992. - Vol. 57. - P. 505-513.
16.
17. Cibula D., Cifkova R., Fanta M. et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome // Hum. Reprod. - 2000. - Vol. 15. - P. 785-789.
18.
19. Wild R.A., Alaupovic P., Parker I.J. Lipid and apolipoprotein abnormalities in hirsute women // Am. J. Obstet. Gynecol. - 1992. - Vol. 166. - P. 1191.
20.
21. Talbott E., Guzick D., Clerici A. et al. Coronary heart disease risk factors in women with polycystic ovary syndrome // Arter. Throm. Vasc. Biol. - 1995. - Vol. 15. - P. 821-826.
22.
23. Balen A.H., Conway G.S., Kaltsas G. et al. Polycystic ovary syndrome. The spectrum of the disorder in 1741 patients // Human Reprod. - 1995. - Vol. 10. - P. 2107-2111.
24.
25. Sampson M., Kong C., Patel A. et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome // Clin. Endocrinol. (Oxf). - 1996. - Vol. 45. - P. 623-629.
26.
27. Atiomo W.U., Bates S.A., Condon J.E. et al. The plasminogen activator system in women with polycystic ovary syndrome // Fertil. Steril. - 1998. - Vol. 69. - P. 236-241.
28.
29. Kelly С.J., Lyall Н., Petrie J.R. et al. А specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome // J. Clin. Endocrinol. Metab. - 2002. - Vol. 87. - P. 3287-3290.
30.
31. Kelly C.C., Lyall H., Petrie J.R. et al. Low grade chronic inflammation in women with polycystic ovarian syndrome // J. Clin. Endocrinol. Metab. - 2001. - Vol. 86. - P. 2453-2455.
32.
33. Ibanez L., Jaramillo A.M., Ferrer A., de Zegher F. High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception // Hum. Reprod. - 2005. - Vol. 20. - P. 2457-2462.
34.
35. Orio Jr. F., Palomba S., Cascella T. et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome // J. Clin. Endocrinol. Metab. - 2005. - Vol. 90. - P. 2-5.
36.
37. Tarkun I., Arslan B.C., Canturk Z. et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation // J. Clin. Endocrinol. Metab. - 2004. - Vol. 89. - P. 5592-5596.
38.
39. Talbott E.O., Zborowski J.V., Rager J.R. et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome // J. Clin. Endocrinol. Metab. - 2004. - Vol. 89, № 11. - P. 5454-5461.
40.
41. Dahlgren E., Janson P.O., Johansson L., Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women // Acta Obstet. Gynecol. Scand. - 1992. - Vol. 71, № 8. - P. 599-604.
42.
43. Pierpoint T., McKeigue P.M., Isaacs A.J. et al. Mortality of women with polycystic ovary syndrome at long-term follow-up // J. Clin. Epidemiol. - 1998. - Vol. 51. - P. 581-586.
44.
45. Wild S., Pierpoint T., McKeigue P., Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study // Clin. Endocrinol. (Oxf). - 2000. - Vol. 52. - P. 595-600.
46.
47. Shaw L.J., Bairey Merz C.N., Aziz R. et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute (NHLBI)- sponsored Women`s Ischemic Syndrome Evaluation (WISE) // J. Clin. Endocrinol. Metab. - 2008. - Vol. 93. - P. 4237-4245.
48.
Review
For citations:
Popova P., Baranova E.V., Grineva E.N. Prevalence of cardiovascular diseases and type 2 diabetes mellitus in perimenopausal women with a history of the polycystic ovary syndrome. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2009;15(2):218-222. (In Russ.) https://doi.org/10.18705/1607-419X-2009-15-2-218-222
Views:
882
Email this article 